Related Experiment Video

Updated: Sep 20, 2026

A Modified In vitro Invasion Assay to Determine the Potential Role of Hormones, Cytokines and/or Growth Factors in Mediating Cancer Cell Invasion
06:36

A Modified In vitro Invasion Assay to Determine the Potential Role of Hormones, Cytokines and/or Growth Factors in Mediating Cancer Cell Invasion

Published on: April 24, 2015

Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated

Richard J Pietras1

  • 1Department of Medicine, Division of Hematology/Oncology, UCLA School of Medicine, and Jonsson Comprehensive Cancer Center, Los Angeles, California 90095-1678, USA. rpietras@ucla.edu

The Breast Journal
|September 13, 2003
PubMed

Insights

Estrogen and growth factors promote breast cancer cell growth by activating receptors and signaling pathways. Targeting these pathways with new therapies may improve breast cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Estrogens and growth factors drive human breast cancer cell proliferation.
  • Receptor activation initiates downstream signaling events crucial for cell growth.
  • Estrogen receptor (ER) phosphorylation state influences its biologic function.

Purpose of the Study:

  • To investigate the interplay between estrogen and growth factor signaling in breast cancer.
  • To explore how growth factor receptor signaling affects ER activity.
  • To highlight the role of angiogenesis in breast cancer progression.

Main Methods:

  • Analysis of signal transduction pathways involving estrogen and growth factor receptors.
  • Investigation of receptor phosphorylation states and their impact on ER activity.
  • Assessment of vascular endothelial growth factor (VEGF) secretion and angiogenesis.

Main Results:

  • Growth factor receptor signaling (HER-2/neu, EGF) modulates ER phosphorylation and activity.
  • Both estrogen and growth factor pathways regulate VEGF secretion, promoting angiogenesis.
  • Molecular interactions significantly impact breast cancer cell growth and survival.

Conclusions:

  • Integration of signal transduction inhibitors with antiestrogen therapies offers a promising new treatment strategy.
  • Sensitive assays for estrogen, HER-2/neu, and EGF receptors are vital for personalized breast cancer therapy.
  • Monitoring tumor-associated angiogenesis is important for selecting optimal antitumor treatments.

More Related Videos

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells04:00

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells

Published on: September 7, 2011

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...